ES2248312T3 - Composiciones que contienen una naftalmida y un agente aniproliferativo. - Google Patents

Composiciones que contienen una naftalmida y un agente aniproliferativo.

Info

Publication number
ES2248312T3
ES2248312T3 ES01926985T ES01926985T ES2248312T3 ES 2248312 T3 ES2248312 T3 ES 2248312T3 ES 01926985 T ES01926985 T ES 01926985T ES 01926985 T ES01926985 T ES 01926985T ES 2248312 T3 ES2248312 T3 ES 2248312T3
Authority
ES
Spain
Prior art keywords
amonafide
antiproliferative
agents
agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01926985T
Other languages
English (en)
Spanish (es)
Inventor
Dennis M. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ChemGenex Pharmaceuticals Inc
Original Assignee
ChemGenex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ChemGenex Pharmaceuticals Inc filed Critical ChemGenex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2248312T3 publication Critical patent/ES2248312T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES01926985T 2000-04-12 2001-04-12 Composiciones que contienen una naftalmida y un agente aniproliferativo. Expired - Lifetime ES2248312T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19710300P 2000-04-12 2000-04-12
US197103P 2000-04-12

Publications (1)

Publication Number Publication Date
ES2248312T3 true ES2248312T3 (es) 2006-03-16

Family

ID=22728064

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01926985T Expired - Lifetime ES2248312T3 (es) 2000-04-12 2001-04-12 Composiciones que contienen una naftalmida y un agente aniproliferativo.

Country Status (10)

Country Link
US (2) US6630173B2 (enExample)
EP (1) EP1274458B1 (enExample)
JP (1) JP2003530431A (enExample)
AT (1) ATE305312T1 (enExample)
AU (1) AU5348301A (enExample)
CA (1) CA2404278C (enExample)
DE (1) DE60113666T2 (enExample)
ES (1) ES2248312T3 (enExample)
HK (1) HK1052874B (enExample)
WO (1) WO2001078705A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
US6693198B2 (en) * 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
US20050239816A1 (en) * 2002-04-22 2005-10-27 Xanthus Life Sciences, Inc. Amonafide salts
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
US20040082788A1 (en) * 2002-07-08 2004-04-29 Chemgenex Therapeutics, Inc. Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
WO2004009092A1 (en) * 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) * 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
US20050192312A1 (en) * 2004-01-30 2005-09-01 Brown Dennis M. Naphthalimide dosing by N-acetyl transferase genotyping
EP1765341A4 (en) * 2004-06-04 2010-04-14 Chemgenex Pharmaceuticals Inc PROCESS FOR TREATING PROLIFERATIVE CELL DISEASE USING NAPHTHALIMIDE AND PARP-1 INHIBITORS
WO2006086693A2 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
US5420137A (en) * 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
FR2673944B1 (fr) * 1991-03-13 1995-03-10 Sanofi Elf Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR20010020611A (ko) * 1997-07-01 2001-03-15 아테로제닉스, 인코포레이티드 항산화제에 의한 과증식질병 치료의 향상
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
US6747061B2 (en) * 2000-03-21 2004-06-08 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物

Also Published As

Publication number Publication date
DE60113666D1 (de) 2005-11-03
EP1274458B1 (en) 2005-09-28
DE60113666T2 (de) 2006-06-14
ATE305312T1 (de) 2005-10-15
CA2404278A1 (en) 2001-10-25
WO2001078705A2 (en) 2001-10-25
US6630173B2 (en) 2003-10-07
US20020025916A1 (en) 2002-02-28
US20040047918A1 (en) 2004-03-11
HK1052874A1 (en) 2003-10-03
AU5348301A (en) 2001-10-30
JP2003530431A (ja) 2003-10-14
EP1274458A2 (en) 2003-01-15
WO2001078705A3 (en) 2002-06-20
HK1052874B (en) 2006-05-04
CA2404278C (en) 2010-03-23

Similar Documents

Publication Publication Date Title
US20120207855A1 (en) Cephalotaxine alkaloid compositions and uses thereof
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
ES2719052T3 (es) Terapia de combinación con un antibiótico antitumoral
CA2404278C (en) Naphthalimide compositions and uses thereof
CN109152839A (zh) 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
AU2001245803A1 (en) Cephalotaxine alkaloid compositions and uses thereof
JP2008540505A (ja) 抗ウィルス剤、抗腫瘍剤または抗寄生虫剤ならびにカルベオール、チモール、オイゲノール、ボルネオールおよびカルバクロールから選択される活性剤を含んでなる製薬組成物
CN103327975A (zh) 用于治疗多形性成胶质母细胞瘤的含有马西替坦的组合物
US10080807B2 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin C
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
ES2955524T3 (es) Una combinación farmacéutica para el tratamiento de un cáncer
US20020040011A1 (en) Naphthoquinone compositions and uses thereof
AU2006202650B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
US20050170015A1 (en) Antiproliferative colchicine compositions and uses thereof
AU2001253483B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
Nalawade et al. Olaparib an anticancer drug: A review
AU2001253483A1 (en) Compositions containing a naphthalimide and an antiproliferative agent
HK1052138B (en) Cephalotaxine alkaloid combination compositions and uses thereof
Matković et al. Topotekan u liječenju recidiva raka jajnika
ES2594499A1 (es) Complejos de Rutenio para el tratamiento del cáncer
KR20100131457A (ko) 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제